BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 24933481)

  • 1. NOTCH and PTEN in prostate cancer.
    Bertrand FE; McCubrey JA; Angus CW; Nutter JM; Sigounas G
    Adv Biol Regul; 2014 Sep; 56():51-65. PubMed ID: 24933481
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Notch-1 signaling is lost in prostate adenocarcinoma and promotes PTEN gene expression.
    Whelan JT; Kellogg A; Shewchuk BM; Hewan-Lowe K; Bertrand FE
    J Cell Biochem; 2009 Aug; 107(5):992-1001. PubMed ID: 19479935
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Notch promotes tumor metastasis in a prostate-specific Pten-null mouse model.
    Kwon OJ; Zhang L; Wang J; Su Q; Feng Q; Zhang XH; Mani SA; Paulter R; Creighton CJ; Ittmann MM; Xin L
    J Clin Invest; 2016 Jul; 126(7):2626-41. PubMed ID: 27294523
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting notch pathway enhances rapamycin antitumor activity in pancreas cancers through PTEN phosphorylation.
    Vo K; Amarasinghe B; Washington K; Gonzalez A; Berlin J; Dang TP
    Mol Cancer; 2011 Nov; 10():138. PubMed ID: 22074495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PI3K/PTEN/AKT signaling regulates prostate tumor angiogenesis.
    Fang J; Ding M; Yang L; Liu LZ; Jiang BH
    Cell Signal; 2007 Dec; 19(12):2487-97. PubMed ID: 17826033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PTEN expression controls cellular response to cetuximab by mediating PI3K/AKT and RAS/RAF/MAPK downstream signaling in KRAS wild-type, hormone refractory prostate cancer cells.
    Bouali S; Chrétien AS; Ramacci C; Rouyer M; Becuwe P; Merlin JL
    Oncol Rep; 2009 Mar; 21(3):731-5. PubMed ID: 19212633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of nuclear PTEN by inhibition of Notch signaling induces G2/M cell cycle arrest in gastric cancer.
    Kim SJ; Lee HW; Baek JH; Cho YH; Kang HG; Jeong JS; Song J; Park HS; Chun KH
    Oncogene; 2016 Jan; 35(2):251-60. PubMed ID: 25823029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preferential chemosensitization of PTEN-mutated prostate cells by silencing the Akt kinase.
    Priulla M; Calastretti A; Bruno P; Azzariti A; Paradiso A; Canti G; Nicolin A
    Prostate; 2007 May; 67(7):782-9. PubMed ID: 17373720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of Notch pathway arrests PTEN-deficient advanced prostate cancer by triggering p27-driven cellular senescence.
    Revandkar A; Perciato ML; Toso A; Alajati A; Chen J; Gerber H; Dimitrov M; Rinaldi A; Delaleu N; Pasquini E; D'Antuono R; Pinton S; Losa M; Gnetti L; Arribas A; Fraering P; Bertoni F; Nepveu A; Alimonti A
    Nat Commun; 2016 Dec; 7():13719. PubMed ID: 27941799
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation of mammalian target of rapamycin signaling pathway markers in minute adenocarcinoma of the prostate.
    Faraj SF; Albadine R; Chaux A; Gonzalez-Roibon N; Hicks J; Humphreys E; Partin A; Netto GJ
    Urology; 2013 Nov; 82(5):1083-9. PubMed ID: 24035134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The TGF-beta, PI3K/Akt and PTEN pathways: established and proposed biochemical integration in prostate cancer.
    Assinder SJ; Dong Q; Kovacevic Z; Richardson DR
    Biochem J; 2009 Jan; 417(2):411-21. PubMed ID: 19099539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Upregulation of miR-153 promotes cell proliferation via downregulation of the PTEN tumor suppressor gene in human prostate cancer.
    Wu Z; He B; He J; Mao X
    Prostate; 2013 May; 73(6):596-604. PubMed ID: 23060044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gata3 antagonizes cancer progression in Pten-deficient prostates.
    Nguyen AH; Tremblay M; Haigh K; Koumakpayi IH; Paquet M; Pandolfi PP; Mes-Masson AM; Saad F; Haigh JJ; Bouchard M
    Hum Mol Genet; 2013 Jun; 22(12):2400-10. PubMed ID: 23428429
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of the PTEN-ARID4B-PI3K pathway reveals the dependency on ARID4B by PTEN-deficient prostate cancer.
    Wu RC; Young IC; Chen YF; Chuang ST; Toubaji A; Wu MY
    Nat Commun; 2019 Sep; 10(1):4332. PubMed ID: 31551414
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Down-modulation of Bcl-2 sensitizes PTEN-mutated prostate cancer cells to starvation and taxanes.
    Calastretti A; Gatti G; Quaresmini C; Bevilacqua A
    Prostate; 2014 Oct; 74(14):1411-22. PubMed ID: 25111376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Jagged1 upregulation in prostate epithelial cells promotes formation of reactive stroma in the Pten null mouse model for prostate cancer.
    Su Q; Zhang B; Zhang L; Dang T; Rowley D; Ittmann M; Xin L
    Oncogene; 2017 Feb; 36(5):618-627. PubMed ID: 27345403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The PTEN Conundrum: How to Target PTEN-Deficient Prostate Cancer.
    Turnham DJ; Bullock N; Dass MS; Staffurth JN; Pearson HB
    Cells; 2020 Oct; 9(11):. PubMed ID: 33105713
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Notch signaling in the prostate: critical roles during development and in the hallmarks of prostate cancer biology.
    Deng G; Ma L; Meng Q; Ju X; Jiang K; Jiang P; Yu Z
    J Cancer Res Clin Oncol; 2016 Mar; 142(3):531-47. PubMed ID: 25736982
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of lncRNAs in prostate cancer development and progression.
    Weiss M; Plass C; Gerhauser C
    Biol Chem; 2014 Nov; 395(11):1275-90. PubMed ID: 25153594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel PI3K inhibitor displays potent preclinical activity against an androgen-independent and PTEN-deficient prostate cancer model established from the cell line PC3.
    Shi M; Zhou X; Zhang Z; Wang M; Chen G; Han K; Cao B; Liu Z; Mao X
    Toxicol Lett; 2014 Aug; 228(3):133-9. PubMed ID: 24831963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.